Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis

BACKGROUND: To date, it has not been ascertained whether shortening the duration of dual antiplatelet therapy (DAPT) can benefit high bleeding risk (HBR) patients. This systematic review and meta-analysis was performed to investigate the safety and efficacy of short (≤ 3 months) DAPT in HBR patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yan, Yuan, Xiaohang, Hu, Xin, Fang, Yan, Jiang, Mengting, Feng, Huanhuan, Gao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2023
Materias:
Clinical Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508065/
https://www.ncbi.nlm.nih.gov/pubmed/35912712
http://dx.doi.org/10.5603/CJ.a2022.0071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508065/
https://www.ncbi.nlm.nih.gov/pubmed/35912712
http://dx.doi.org/10.5603/CJ.a2022.0071

Ejemplares similares